KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Other Operating Expenses (2020 - 2025)

Ginkgo Bioworks Holdings' Other Operating Expenses history spans 6 years, with the latest figure at $821000.0 for Q4 2025.

  • For Q4 2025, Other Operating Expenses fell 21.73% year-over-year to $821000.0; the TTM value through Dec 2025 reached -$4.5 million, down 216.98%, while the annual FY2025 figure was -$4.5 million, 216.98% down from the prior year.
  • Other Operating Expenses reached $821000.0 in Q4 2025 per DNA's latest filing, up from -$163000.0 in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $7.1 million in Q2 2021 to a low of -$4.9 million in Q3 2021.
  • Average Other Operating Expenses over 5 years is $719100.0, with a median of $525500.0 recorded in 2022.
  • Peak YoY movement for Other Operating Expenses: skyrocketed 1301.74% in 2023, then crashed 312.85% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at -$2.6 million in 2021, then surged by 337.33% to $6.2 million in 2022, then tumbled by 98.49% to $93000.0 in 2023, then skyrocketed by 1027.96% to $1.0 million in 2024, then decreased by 21.73% to $821000.0 in 2025.
  • Per Business Quant, the three most recent readings for DNA's Other Operating Expenses are $821000.0 (Q4 2025), -$163000.0 (Q3 2025), and -$896000.0 (Q2 2025).